-
Mashup Score: 0FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease - 8 day(s) ago
The FDA has approved 2 denosumab biosimilars for all indications of their respective reference medications.
Source: www.onclive.comCategories: General Medicine NewsTweet
-
Mashup Score: 2Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS - 8 day(s) ago
Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS @MDAndersonNews @ASH_hematology #ASH24 #lymsm #hematology https://t.co/KAHhJKgJYs
-
-
Mashup Score: 3Lisaftoclax Plus Azacitidine Shows Clinical Activity and Manageable Safety in Higher-Risk MDS - 8 day(s) ago
Lisaftoclax plus azacitidine demonstrated clinical activity and was safe in higher-risk MDS.
Source: www.onclive.comCategories: General Medicine NewsTweet-
The combination of lisaftoclax plus azacitidine demonstrated clinical activity and was safe in higher-risk MDS, according to findings from a phase 1b/2 study. #mpnsm #oncology https://t.co/KGCb3UHnlK
-
-
Mashup Score: 0Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study - 8 day(s) ago
Dr. Eric Singhi presents preliminary findings from the Phase I/II SOHO-01 trial, demonstrating that the oral HER2-targeted tyrosine kinase inhibitor BAY 2927088 achieves high response rates and durable disease control in patients with pretreated HER2-mutant NSCLC, with a manageable safety profile.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Tune in to hear @lungoncdoc of @MDAndersonNews present preliminary findings from the Phase I/II SOHO-01 trial of BAY 2927088 in patients with pretreated HER2-mutant NSCLC. Watch more here: https://t.co/cZIjNfLAdm https://t.co/adN2bxfgOE
-
-
Mashup Score: 6FDA Approves First-Line Tislelizumab Plus Chemotherapy for Unresectable or Metastatic ESCC - 8 day(s) ago
The FDA has approved tislelizumab-jsgr (Tevimbra) plus platinum-containing chemotherapy for the frontline treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1.
Source: www.onclive.comCategories: General Medicine NewsTweet-
🚨BREAKING🚨: @US_FDA Approves First-Line Tislelizumab Plus Chemotherapy for Unresectable or Metastatic ESCC. Learn more: https://t.co/R08ErZB0RS https://t.co/RlbdO72qLL
-
-
Mashup Score: 1Quizartinib Plus Chemotherapy Is Set to Be Evaluated in FLT3-ITD-Negative AML in Phase 3 Trial - 8 day(s) ago
Quizartinib with 7+3 chemotherapy was safe and effective in patients with FLT3-ITD–negative AML, leading to the initiation of the phase 3 QuANTUM-Wild trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
The efficacy and safety demonstrated by quizartinib with 7+3 chemotherapy in patients with FLT3-ITD–negative AML supports the initiation of the phase 3 QuANTUM-Wild trial for this patient population. #leusm #oncology https://t.co/GehiOY5ZsV
-
-
Mashup Score: 0Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc - 8 day(s) ago
Drs Park and LaCasce discuss advancements in Hodgkin and non-Hodgkin lymphoma management, including efforts to reduce long-term toxicity.
Source: www.onclive.comCategories: General Medicine NewsTweet-
In this episode of @MedNewsWeek, @CParkMD @DrLaCasce discuss advancements in Hodgkin and NHL management, including efforts to reduce long-term toxicity. LISTEN: 🎧 https://t.co/vTXlc1pSfq @NortonHealthIT @DanaFarberNews #lymsm #oncology https://t.co/2jAoWS6z76
-
-
Mashup Score: 1
Panelists discuss how the resectability of stage III non-small cell lung cancer tumors remains controversial, particularly regarding the role of surgery in multi-station N2 disease and the optimal sequencing of multimodality therapy.
Source: www.onclive.comCategories: General Medicine NewsTweet-
Tune into hear @RamalingamMD of @WinshipAtEmory, @DrewMoghanaki of @UCLAHealth and @jdoningtonmd of @UChicagoMed discuss how the resectability of stage III non-small cell lung cancer tumors remains controversial. Watch more here: https://t.co/h4GNMGgBlh
-
-
Mashup Score: 1
Benjamin L. Maughan, MD, PharmD, discusses the need for improved update of treatment intensification in metastatic hormone-sensitive prostate cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet-
.@maughanonc on the Need for Consensus on Treatment Intensification in mHSPC #pcsm #oncology https://t.co/r9lZDiXptf
-
-
Mashup Score: 0Dr Morgans on Standardizing the Management of Bone/Cardiac Health With Systemic Therapy in Prostate Cancer - 8 day(s) ago
Alicia Morgans, MD, MPH, discusses the importance of managing bone and cardiac health in patients with prostate cancer receiving systemic therapy.
Source: www.onclive.comCategories: General Medicine NewsTweet-
.@CaPsurvivorship on Standardizing the Management of Bone/Cardiac Health With Systemic Therapy in Prostate Cancer #pcsm #oncology https://t.co/SZoFrgLkkn
-
FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease #oncology #medtwitter https://t.co/F29Q3jhhjl